Prostate cancer treatment best based on life-expectancy
This article was originally published in Clinica
Executive Summary
Prostate cancer patients with "long life-expectancies who are not a great surgical risk and who have a preference to undergo surgery" are most likely to benefit from radical prostatectomy. Those with "long life expectancy, no risk factors for the treatment, and a preference for radiation therapy" will most likely benefit from this type of treatment, while patients with shorter life-expectancy and/or low grade tumours may benefit most from surveillance. These are the conclusions of the Prostate Cancer Clinical Guidelines Panel of the American Urological Association (Journal of Urology, Vol. 154, pp. 2144-2148).
You may also be interested in...
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.